Autoimmune Encephalitis clinical trials at UCSF
1 research study open to eligible people
Autoimmune encephalitis is when the immune system wrongly attacks the brain. UCSF is conducting research to assess the effects of Satralizumab on two particular types of this disease. The study also investigates the drug's safety and how it functions inside the body.
Showing trials for
(PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis
open to eligible people ages 12 years and up
The purpose of this study is to assess the efficacy, safety, PK, and PD of satralizumab in participants with NMDAR and LGI1 encephalitis.
San Francisco, California and other locations
Last updated: